Sign in Subscribe
Stock exchanges

Immunovant, Inc. Files Form 8-K on Employment Agreement with Eric Venker

Strategic Insights

— 2 min read

Immunovant, Inc. has filed a Form 8-K with the U.S. Securities and Exchange Commission, reporting the employment agreement between the company and Eric Venker, M.D., Pharm.D., who was appointed as Chief Executive Officer and principal executive officer on April 21, 2025. The agreement outlines the terms of Venker's employment, including his compensation and potential equity awards.

Key Takeaways:

  • Immunovant, Inc. has filed a Form 8-K with the SEC on July 29, 2025, disclosing the employment agreement with Eric Venker, M.D., Pharm.D.
  • The agreement, dated July 28, 2025, outlines the terms of Venker's employment as Chief Executive Officer and principal executive officer.
  • Venker will receive an annual base salary of $672,000, with a target annual performance bonus of 72.25% of his base salary.
  • He will also receive equity awards consisting of 1,300,000 common stock options, 189,900 common stock options with a grant date value of $2,250,000, and 1,475,000 capped value appreciation rights (CVARs).
  • The CVARs will vest in stages, with 25% vesting on April 1, 2026, and the remainder vesting quarterly over the next 12 months.
  • The CVARs will also be subject to performance requirements and a knock-in requirement, which states that the price of Immunovant's common shares must be equal to or greater than $16.76 per share on a vesting date.
  • Upon vesting, the CVARs will entitle Venker to a payment equal to the product of the number of vested CVARs and the CVAR amount, which will be settled into shares of Immunovant's common stock.
  • 87.25% of the shares issued to Venker will be subject to a two-year holding period, during which he cannot sell or transfer the shares without prior consent from the Board.
  • Venker is also eligible for severance benefits under the employment agreement, including a continuation of his base salary and other benefits for 12 months following termination.

Statistics:

  • $672,000: Venker's annual base salary
  • $289,500: Target annual performance bonus
  • 1,300,000: Number of common stock options granted
  • 189,900: Number of common stock options granted with a grant date value of $2,250,000
  • 1,475,000: Number of capped value appreciation rights (CVARs) granted
  • $16.76: Price of Immunovant's common shares required for CVAR vesting
  • 12 months: Duration of the severance benefits period

Sources:

  • Immunovant, Inc. Form 8-K filing, dated July 29, 2025
  • Immunovant, Inc. Employment Agreement, dated July 28, 2025 (Exhibit 10.1 to the Form 8-K filing)

Read more